Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs Fumaric Acid Esters and Methotrexate in Systemic-Naive Psoriasis
NCT02634801Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2016
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixekizumab in plaque psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With a >=75% Improvement in Psoriasis Area and Severity Index at 24 weeks. Started Jan 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02634801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634801.